Overview

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Treatments:

durvalumab
lenvatinib
tremelimumab